Fulgent Genetics Inc reports results for the quarter ended June 30 - Earnings Summary

Fulgent Genetics

31/07/2026 07:16

Fulgent Genetics Inc FLGT.OQ reported a quarterly adjusted loss of 58 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 7 cents.  The lone analyst forecast for the quarter was for a loss of 46 cents per share. 
Revenue rose 4.4% to $85.39 million from a year ago; analysts expected $94.00 million. 
Fulgent Genetics Inc's reported EPS for the quarter was a loss of $1.05​.
The company reported a quarterly loss of $29.53 million.
Fulgent Genetics Inc shares had fallen by 1.5% this quarter and lost 23.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 318.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the healthcare facilities & services peer group is  "buy."
Wall Street's median 12-month price target for Fulgent Genetics Inc is $15.00, about 34.7% below its last closing price of $20.21
This summary was machine generated from LSEG data July 31 at 06:16 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.46
-0.58
Missed
Mar. 31 2026 
-0.10
-0.36
Missed
Dec. 31 2025 
0.03
0.16
Beat
Sep. 30 2025 
-0.22
0.14
Beat